MoonLake Immunotherapeutics reported Q3 2026 financial results and announced the submission of a Biologics License Application (BLA) to the FDA for sonelokimab in hidradenitis suppurativa. The company ended the quarter with $498.5 million in cash and equivalents, providing a projected cash runway into mid-2028.
MoonLake Immunotherapeutics has submitted a Biologics License Application (BLA) to the FDA for its tri-specific nanobody sonelokimab. The application seeks approval for the treatment of moderate-to-severe hidradenitis suppurativa in adults and pediatric patients. The company expects notification regarding the acceptance of the BLA for review within approximately 60 days.